SCHEMBL26554384

SCHEMBL26554384

CC[C@H]1O[C@@H](n2ccc(=O)cc2)[C@H](OC(=O)c2ccccc2)[C@@H]1C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
USP2 O75604 1/20 0.41
POLB P06746 1/20 0.41
LGALS9 O00182 1/20 0.40
LGALS1 P09382 1/20 0.40
LGALS3 P17931 1/20 0.40
LGALS7; LGALS7B P47929 1/20 0.40
GAPDH P04406 2/20 0.38
ALDH1A1 P00352 2/20 0.35
CARM1 Q86X55 1/20 0.35
PRMT6 Q96LA8 1/20 0.35
PTPN1 P18031 2/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
CA9 Q16790 1/20 0.35
RNASE1 P07998 1/20 0.34
LMNA P02545 1/20 0.34
HTR3E A5X5Y0 1/20 0.34
HTR3B O95264 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26554372 0.85 LMNA (0.36) ALDH1A1PTPN1CA1CA2CA9
SCHEMBL26554463 0.84 GAPDH (0.41) MEN1KMT2AUSP2POLBLGALS9
SCHEMBL27055211 0.81 CDA (0.44) MEN1KMT2AUSP2POLBLGALS9
SCHEMBL25824039 0.81 CDA (0.44) MEN1KMT2AUSP2POLBLGALS9
SCHEMBL16904879 0.81 MEN1 (0.51) MEN1KMT2AUSP2POLBGAPDH
SCHEMBL25504874 0.81 MEN1 (0.51) MEN1KMT2AUSP2POLBGAPDH
SCHEMBL25504929 0.81 MEN1 (0.51) MEN1KMT2AUSP2POLBGAPDH
SCHEMBL25504886 0.81 MEN1 (0.51) MEN1KMT2AUSP2POLBGAPDH
SCHEMBL12404716 0.81 MEN1 (0.51) MEN1KMT2AUSP2POLBGAPDH
SCHEMBL11442315 0.80 USP2 (0.62) MEN1KMT2AUSP2POLBLGALS9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230365970-A1 Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof ALIGOS THERAPEUTICS, INC. (US) 2023-11-16 US disclosed
US-20230332153-A1 Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof ALIGOS THERAPEUTICS, INC. (US) 2023-10-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230365970-A1 Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof NSUN2, SNRPA, SNRPF MEN1 4401/4885KMT2A 561/4885USP2 3252/4885
US-20230332153-A1 Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof NSUN2, SNRPA, SNRPF MEN1 4401/4885KMT2A 561/4885USP2 3252/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.